Remove tag second-nature
article thumbnail

Cannabinoids receptors: popular preclinical target but banned in 137 countries

Pharmaceutical Technology

The two types of cannabinoids targeting cannabinoid receptors are endocannabinoids, which are naturally occurring endogenous ligands and synthetic cannabinoids, which are designed in a laboratory. This is closely followed by CB2 receptors in second place. Cannabinoid-based drugs are derived from compounds found in the cannabis plant.

article thumbnail

Can gene therapies for haemophilia defend their high price tags?

Pharmaceutical Technology

million price tag. This is due to the often-burdensome nature of factor VIII replacement, which is also associated with high bleeding rates, explains Rind. after the first year, slumping to 23 after the second. The post Can gene therapies for haemophilia defend their high price tags? million ($1.8 million at the time).

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

IBM sells off large parts of Watson Health business

pharmaphorum

IBM said the sell-off is tagged as “a clear next step” as it focuses on its platform-based hybrid cloud and artificial intelligence strategy, but it’s no secret that Watson Health has failed to live up to its early promise. IBM’s step back from health comes as tech rivals are still piling into the sector.

Radiology 111
article thumbnail

Company Spotlight: Cue Biopharma Innovates in the Immunotherapy Space with its Immuno-STAT Platform

XTalks

T cell transfer or adoptive/immune cell therapy : these enhance the natural ability of T cells to fight infection, cancer or other disease processes. Nature by Design. The T cell-APC interaction is central to the equation – it is the reaction in nature that happens as the first signal, which sets the specificity of the reaction.

Protein 98
article thumbnail

Roche’s quantitative COVID-19 antibody test; Janssen buys a gene therapy asset; Zimmer Acquires A&E Medical; Glaucoma research study: Merck chooses TriNKET cancer immunotherapy program; Ovid fails Angelman phase 3 study

Delveinsight

AMD Patients often have low levels of CD59, which is a protein that protects the retina from damage caused by a vital part of the body’s natural immune response called complement. It has already succeeded in a phase 1 test, with a second in patients with wet AMD. Merck chooses TriNKET cancer immunotherapy program.

article thumbnail

Beam makes USD 120M bet; GRAIL and Quest announce the collaboration; Brain organoids mimic infant’s brains; Improvement in T cells to kill cancer

Delveinsight

once Galleri becomes accessible in the second quarter of 2021. Daniel Geschwind of UCLA and Dr. Sergiu Pasca of Stanford University, conducted an extensive genetic analysis of organoids grown for up to 20 months in a lab dish per the new study, which was published in Nature Neuroscience.

DNA 52
article thumbnail

Ep. 008 – Vlad Mkrtumyan Podcast Transcript

Pharma Marketing Network

Number one, there’s the content right, so when you’re searching coffee internet you’re reading something some kind of content and that’s the first thing you’ve got to create and optimize the second thing the second component besides content is link building, right?

Doctors 52